Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hop S. Tran Cao is active.

Publication


Featured researches published by Hop S. Tran Cao.


Annals of Surgery | 2017

A Prospective Randomized Multicenter Trial of Distal Pancreatectomy with and Without Routine Intraperitoneal Drainage

George Van Buren; Mark Bloomston; Carl Schmidt; Stephen W. Behrman; Nicholas J. Zyromski; Chad G. Ball; Katherine A. Morgan; Steven J. Hughes; Paul J. Karanicolas; John Allendorf; Charles M. Vollmer; Quan Ly; Kimberly M. Brown; Vic Velanovich; Jordan M. Winter; Amy McElhany; Peter Muscarella; C.M. Schmidt; Michael G. House; Elijah Dixon; Mary Dillhoff; Jose G. Trevino; Julie Hallet; Natalie G. Coburn; Attila Nakeeb; Kevin E. Behrns; Aaron R. Sasson; Eugene P. Ceppa; Sherif Abdel-Misih; Taylor S. Riall

Objective: The objective of this study was to test the hypothesis that distal pancreatectomy (DP) without intraperitoneal drainage does not affect the frequency of grade 2 or higher grade complications. Background: The use of routine intraperitoneal drains during DP is controversial. Prior to this study, no prospective trial focusing on DP without intraperitoneal drainage has been reported. Methods: Patients undergoing DP for all causes at 14 high-volume pancreas centers were preoperatively randomized to placement of a drain or no drain. Complications and their severity were tracked for 60 days and mortality for 90 days. The study was powered to detect a 15% positive or negative difference in the rate of grade 2 or higher grade complications. All data were collected prospectively and source documents were reviewed at the coordinating center to confirm completeness and accuracy. Results: A total of 344 patients underwent DP with (N = 174) and without (N = 170) the use of intraperitoneal drainage. There were no differences between cohorts in demographics, comorbidities, pathology, pancreatic duct size, pancreas texture, or operative technique. There was no difference in the rate of grade 2 or higher grade complications (44% vs. 42%, P = 0.80). There was no difference in clinically relevant postoperative pancreatic fistula (18% vs 12%, P = 0.11) or mortality (0% vs 1%, P = 0.24). DP without routine intraperitoneal drainage was associated with a higher incidence of intra-abdominal fluid collection (9% vs 22%, P = 0.0004). There was no difference in the frequency of postoperative imaging, percutaneous drain placement, reoperation, readmission, or quality of life scores. Conclusions: This prospective randomized multicenter trial provides evidence that clinical outcomes are comparable in DP with or without intraperitoneal drainage.


Journal of Surgical Oncology | 2017

Impact of pancreatectomy on long‐term patient‐reported symptoms and quality of life in recurrence‐free survivors of pancreatic and periampullary neoplasms

Jordan M. Cloyd; Hop S. Tran Cao; Maria Q.B. Petzel; Jason W. Denbo; Nathan H. Parker; Graciela M. Nogueras-Gonzalez; Joseph S. Liles; Michael P. Kim; Jeffrey E. Lee; Jean Nicolas Vauthey; Thomas A. Aloia; Jason B. Fleming; Matthew H. Katz

Long term patient‐reported symptoms and quality of life (QOL) are important outcome metrics following cancer operations, but have been poorly described in patients who have previously undergone pancreatectomy.


Cancer | 2018

The role of surgery and adjuvant therapy in lymph node‐positive cancers of the gallbladder and intrahepatic bile ducts

Hop S. Tran Cao; Qianzi Zhang; Yvonne H. Sada; Christy Chai; Steven A. Curley; Nader N. Massarweh

Lymph node metastasis is a poor prognostic factor for biliary tract cancers (BTCs). The optimal management of patients who have BTC with positive regional lymph nodes, including the impact of surgery and adjuvant therapy (AT), is unclear.


Journal of the American Society for Mass Spectrometry | 2017

Detection of Metastatic Breast and Thyroid Cancer in Lymph Nodes by Desorption Electrospray Ionization Mass Spectrometry Imaging

Jialing Zhang; Clara L. Feider; Chandandeep Nagi; Wendong Yu; Stacey A. Carter; James W. Suliburk; Hop S. Tran Cao; Livia S. Eberlin

AbstractAmbient ionization mass spectrometry has been widely applied to image lipids and metabolites in primary cancer tissues with the purpose of detecting and understanding metabolic changes associated with cancer development and progression. Here, we report the use of desorption electrospray ionization mass spectrometry (DESI-MS) to image metastatic breast and thyroid cancer in human lymph node tissues. Our results show clear alterations in lipid and metabolite distributions detected in the mass spectra profiles from 42 samples of metastatic thyroid tumors, metastatic breast tumors, and normal lymph node tissues. 2D DESI-MS ion images of selected molecular species allowed discrimination and visualization of specific histologic features within tissue sections, including regions of metastatic cancer, adjacent normal lymph node, and fibrosis or adipose tissues, which strongly correlated with pathologic findings. In thyroid cancer metastasis, increased relative abundances of ceramides and glycerophosphoinisitols were observed. In breast cancer metastasis, increased relative abundances of various fatty acids and specific glycerophospholipids were seen. Trends in the alterations in fatty acyl chain composition of lipid species were also observed through detailed mass spectra evaluation and chemical identification of molecular species. The results obtained demonstrate DESI-MSI as a potential clinical tool for the detection of breast and thyroid cancer metastasis in lymph nodes, although further validation is needed. Graphical AbstractDesorption electrospray ionization mass spectrometry imaging is used to differentiate metastatic cancer from adjacent lymph node tissue


JAMA Surgery | 2017

Management of Stage I Squamous Cell Carcinoma of the Anal Canal

Christy Chai; Hop S. Tran Cao; Samir S. Awad; Nader N. Massarweh

Importance The incidence of squamous cell carcinoma of the anal canal (SCCAC) is increasing. Although standard management of SCCAC includes the use of concurrent chemotherapy and radiotherapy (chemoradiotherapy), data are lacking on potentially less morbid, alternative management strategies, such as local excision, among patients with node-negative T1 disease. Objectives To examine the use of local excision among patients with T1 SCCAC and to compare overall survival relative to those who received standard treatment with chemoradiotherapy. Design, Setting, and Participants This retrospective cohort study assessed 2243 patients in the National Cancer Database (2004-2012) between 18 and 80 years of age with T1N0M0 SCCAC. The association between the type of treatment received and overall risk of death was evaluated using multivariable Cox proportional hazards regression models. Data analysis was performed from June 29, 2016, to April 17, 2017. Main Outcomes and Measures Overall survival. Results Among 2243 patients with T1N0 SCCAC, 503 (22.4%) were treated with local excision alone (mean [SD] age, 54.5 [12.1] years; 240 [47.7%] male; 419 [83.3%] white) and 1740 with chemoradiotherapy (mean [SD] age, 57.0 [10.6] years; 562 [32.3%] male; 1547 [88.9%] white). Among those treated with chemoradiotherapy, 12 patients underwent a subsequent abdominoperineal resection. There was a statistically significant increase in the use of local excision during the study period (34 [17.3%] in 2004 to 68 [30.8%] in 2012; trend test, P < .001). This increase in use was observed among patients with primary tumors that measured 1 cm or smaller and greater than 1 cm to 2 cm or smaller (trend test, P < .001 for both). Overall survival at 5 years was not significantly different for the 2 management strategies (85.3% in the local excision cohort and 86.8% in the chemoradiotherapy cohort; log-rank test, P = .93). Overall risk of death was not significantly different for local excision alone relative to that for treatment with chemoradiotherapy (hazard ratio, 1.06; 95% CI, 0.78-1.44). These findings were robust when stratified by tumor size and when patients who underwent abdominoperineal resection after chemoradiotherapy were excluded. Conclusions and Relevance The use of local excision alone for the management of T1N0 SCCAC has significantly increased over time, with no clear decrement in overall survival. Because local excision may represent a lower-cost, less morbid treatment option for select patients with SCCAC, future studies are needed to better delineate its role and efficacy relative to the current standard of chemoradiotherapy.


JAMA Surgery | 2017

Association of the Addition of Oral Antibiotics to Mechanical Bowel Preparation for Left Colon and Rectal Cancer Resections With Reduction of Surgical Site Infections

Elaine Vo; Nader N. Massarweh; Christy Chai; Hop S. Tran Cao; Nader Zamani; Sherry Abraham; Kafayat Adigun; Samir S. Awad

Importance Surgical site infections (SSIs) after colorectal surgery remain a significant complication, particularly for patients with cancer, because they can delay the administration of adjuvant therapy. A combination of oral antibiotics and mechanical bowel preparation (MBP) is a potential, yet controversial, SSI prevention strategy. Objective To determine the association of the addition of oral antibiotics to MBP with preventing SSIs in left colon and rectal cancer resections and its association with the timely administration of adjuvant therapy. Design, Setting, and Participants A retrospective review was performed of 89 patients undergoing left colon and rectal cancer resections from October 1, 2013, to December 31, 2016, at a single institution. A bowel regimen of oral antibiotics and MBP (neomycin sulfate, metronidazole hydrochloride, and magnesium citrate) was implemented August 1, 2015. Patients receiving MBP and oral antibiotics and those undergoing MBP without oral antibiotics were compared using univariate analysis. Multivariable logistic regression controlling for factors that may affect SSIs was used to evaluate the association between use of oral antibiotics and MBP and the occurrence of SSIs. Main Outcomes and Measures Surgical site infections within 30 days of the index procedure and time to adjuvant therapy. Results Of the 89 patients (5 women and 84 men; mean [SD] age, 65.3 [9.2] years) in the study, 49 underwent surgery with MBP but without oral antibiotics and 40 underwent surgery with MBP and oral antibiotics. The patients who received oral antibiotics and MBP were younger than those who received only MBP (mean [SD] age, 62.6 [9.1] vs 67.5 [8.8] years; P = .01), but these 2 cohorts of patients were otherwise similar in baseline demographic, clinical, and cancer characteristics. Surgical approach (minimally invasive vs open) and case type were similarly distributed; however, the median operative time of patients who received oral antibiotics and MBP was longer than that of patients who received MBP only (391 minutes [interquartile range, 302-550 minutes] vs 348 minutes [interquartile range, 248-425 minutes]; P = .03). The overall SSI rate was lower for patients who received oral antibiotics and MBP than for patients who received MBP only (3 [8%] vs 13 [27%]; P = .03), with no deep or organ space SSIs or anastomotic leaks in patients who received oral antibiotics and MBP compared with 9 organ space SSIs (18%; P = .004) and 5 anastomotic leaks (10%; P = .06) in patients who received MBP only. Despite this finding, there was no difference in median days to adjuvant therapy between the 2 cohorts (60 days [interquartile range, 46-73 days] for patients who received MBP only vs 72 days [interquartile range, 59-85 days] for patients who received oral antibiotics and MBP; P = .13). Oral antibiotics and MBP (odds ratio, 0.11; 95% CI, 0.02-0.86; P = .04) and minimally invasive surgery (odds ratio, 0.22; 95% CI, 0.05-0.89; P = .03) were independently associated with reduced odds of SSIs. Conclusions and Relevance The combination of oral antibiotics and MBP is associated with a significant decrease in the rate of SSIs and should be considered for patients undergoing elective left colon and rectal cancer resections.


Annals of Surgery | 2017

National Quality Forum Colon Cancer Quality Metric Performance

Meredith C. Mason; George J. Chang; Laura A. Petersen; Yvonne H. Sada; Hop S. Tran Cao; Christy Chai; David H. Berger; Nader N. Massarweh

Objective: To evaluate the impact of care at high-performing hospitals on the National Quality Forum (NQF) colon cancer metrics. Background: The NQF endorses evaluating ≥12 lymph nodes (LNs), adjuvant chemotherapy (AC) for stage III patients, and AC within 4 months of diagnosis as colon cancer quality indicators. Data on hospital-level metric performance and the association with survival are unclear. Methods: Retrospective cohort study of 218,186 patients with resected stage I to III colon cancer in the National Cancer Data Base (2004–2012). High-performing hospitals (>75% achievement) were identified by the proportion of patients achieving each measure. The association between hospital performance and survival was evaluated using Cox shared frailty modeling. Results: Only hospital LN performance improved (15.8% in 2004 vs 80.7% in 2012; trend test, P < 0.001), with 45.9% of hospitals performing well on all 3 measures concurrently in the most recent study year. Overall, 5-year survival was 75.0%, 72.3%, 72.5%, and 69.5% for those treated at hospitals with high performance on 3, 2, 1, and 0 metrics, respectively (log-rank, P < 0.001). Care at hospitals with high metric performance was associated with lower risk of death in a dose-response fashion [0 metrics, reference; 1, hazard ratio (HR) 0.96 (0.89–1.03); 2, HR 0.92 (0.87–0.98); 3, HR 0.85 (0.80–0.90); 2 vs 1, HR 0.96 (0.91–1.01); 3 vs 1, HR 0.89 (0.84–0.93); 3 vs 2, HR 0.95 (0.89–0.95)]. Performance on metrics in combination was associated with lower risk of death [LN + AC, HR 0.86 (0.78–0.95); AC + timely AC, HR 0.92 (0.87–0.98); LN + AC + timely AC, HR 0.85 (0.80–0.90)], whereas individual measures were not [LN, HR 0.95 (0.88–1.04); AC, HR 0.95 (0.87–1.05)]. Conclusions: Less than half of hospitals perform well on these NQF colon cancer metrics concurrently, and high performance on individual measures is not associated with improved survival. Quality improvement efforts should shift focus from individual measures to defining composite measures encompassing the overall multimodal care pathway and capturing successful transitions from one care modality to another.


Surgery | 2017

Value of lymph node positivity in treatment planning for early stage pancreatic cancer

Hop S. Tran Cao; Qianzi Zhang; Yvonne H. Sada; Eric J. Silberfein; Cary Hsu; George Van Buren; Christy Chai; Matthew H. Katz; William E. Fisher; Nader N. Massarweh

Background: Multimodal therapy is recommended for early stage pancreatic cancer, although whether all patients benefit and the optimal timing of chemotherapy remain unclear. Methods: Retrospective cohort study of patients aged 18–79 years with stage I‐II pancreatic ductal adenocarcinoma in the National Cancer Database (2004–2012). Patients were grouped based on treatment strategy as surgery only, adjuvant, and preoperative. Accuracy of nodal staging and rate of nodal downstaging were ascertained using pretreatment clinical and postresection pathologic nodal status data. Association between overall risk of death and treatment strategy was evaluated with multivariable Cox regression. Results: Among 19,031 patients, 31.1% underwent surgery only, 59.6% received adjuvant, and 9.3% preoperative therapy. Based on patients receiving upfront surgery, clinical nodal staging bore sensitivity, specificity, positive predictive value, and negative predictive value of 46.2%, 95.7%, 95.1%, and 49.8%, respectively. Preoperative therapy downstaged 38% of cN1 patients to ypN0; 5‐year overall survival for this group was 27.2% vs 12.3% for ypN1 patients (P < .001). Relative to surgery only, adjuvant (HR 0.75, 95% CI [0.71–0.78]) and preoperative therapy (HR 0.66 [0.60–0.73]) were associated with lower risk of death among patients with pN1, but not pN0 (adjuvant—HR 1.01 [0.94–1.09]; preoperative—HR 1.10 [0.99–1.22]), disease. Conclusion: Our data provide strong support for preoperative chemotherapy for patients with node‐positive pancreatic cancer, one third of whom may be downstaged. Among those with seemingly node‐negative disease, half will be understaged with current clinical staging modalities. These results should be considered when planning treatment for patients with early stage pancreatic cancer.


Scientific Reports | 2017

A new mild hyperthermia device to treat vascular involvement in cancer surgery

Matthew Ware; Lam Nguyen; Justin J. Law; Martyna Krzykawska-Serda; Kimberly Taylor; Hop S. Tran Cao; Andrew O. Anderson; Merlyn Pulikkathara; Jared M. Newton; Jason Chak-Shing Ho; Rosa F. Hwang; Kimal Rajapakshe; Cristian Coarfa; Shixia Huang; Dean P. Edwards; Steven A. Curley; Stuart J. Corr

Surgical margin status in cancer surgery represents an important oncologic parameter affecting overall prognosis. The risk of disease recurrence is minimized and survival often prolonged if margin-negative resection can be accomplished during cancer surgery. Unfortunately, negative margins are not always surgically achievable due to tumor invasion into adjacent tissues or involvement of critical vasculature. Herein, we present a novel intra-operative device created to facilitate a uniform and mild heating profile to cause hyperthermic destruction of vessel-encasing tumors while safeguarding the encased vessel. We use pancreatic ductal adenocarcinoma as an in vitro and an in vivo cancer model for these studies as it is a representative model of a tumor that commonly involves major mesenteric vessels. In vitro data suggests that mild hyperthermia (41–46 °C for ten minutes) is an optimal thermal dose to induce high levels of cancer cell death, alter cancer cell’s proteomic profiles and eliminate cancer stem cells while preserving non-malignant cells. In vivo and in silico data supports the well-known phenomena of a vascular heat sink effect that causes high temperature differentials through tissues undergoing hyperthermia, however temperatures can be predicted and used as a tool for the surgeon to adjust thermal doses delivered for various tumor margins.


Journal of Surgical Research | 2018

Prognostic value of neoadjuvant treatment response in locally advanced rectal cancer

Yvonne H. Sada; Hop S. Tran Cao; George J. Chang; Avo Artinyan; Benjamin Leon Musher; Brandon G. Smaglo; Nader N. Massarweh

Collaboration


Dive into the Hop S. Tran Cao's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Christy Chai

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Yvonne H. Sada

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

George Van Buren

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Matthew H. Katz

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Qianzi Zhang

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Samir S. Awad

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Amy McElhany

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Carl Schmidt

The Ohio State University Wexner Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge